Form DEF 14A BioXcel Therapeutics, For: May 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioXcel Therapeutics (BTAI) PT Raised to $76 at Jefferies
April 6, 2022 11:40 AM EDTJefferies analyst Chris Howerton raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $76.00 (from $73.00) while maintaining a Buy rating on FDA Approval of IGALMI Sublingual Film.
The analyst noted the label was broad, pricing is soon, and trade-launch in Q3.
... More